Full Press Release Details
Pharmaceuticals to Present at the Canaccord Genuity Rare Disease and
Bio-Pharma One on One Day
VICTORIA, British Columbia--(BUSINESS WIRE)--January 29, 2016--Aurinia
Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) today announced that its
President and CEO Stephen Zaruby will attend and discuss the corporate
overview of the company at the Canaccord Genuity Rare Disease and
Bio-Pharma One on One Day, taking place February 2nd, 2016 in New York
at the Omni Berkshire Place Hotel.
Aurinia Presentation Details
Date: Tuesday, Feb 2nd, 2016
Time: 10:25 a.m. Eastern
New York Omni Berkshire Place Hotel
Aurinia is a clinical stage pharmaceutical company focused on the global
nephrology market. It is currently collecting data in its 265 patient
Phase 2b clinical trial to evaluate the efficacy of its drug,
voclosporin, as a treatment for LN. LN is an inflammation of the
kidneys, that if inadequately treated can lead to end-stage renal
disease, making LN a serious and potentially life-threatening condition.
Voclosporin is a novel and potentially best-in-class calcineurin
inhibitor ("CNI") with extensive clinical data in over 2,000 patients in
other indications. Voclosporin is made by a modification of a single
amino acid of the cyclosporine molecule (a CNI approved for use in
transplant patients since 1983). This modification results in a more
predictable pharmacokinetic and pharmacodynamic relationship, an
increase in potency vs. cyclosporine, an altered metabolic profile, and
potential for flat dosing.
Visit www.auriniapharma.com for more information.
Aurinia Pharmaceuticals Inc.
Chief Operating Officer
Stephen W. Zaruby, 250-708-4293
Chief Executive Officer
Financial Communications Inc.
Barry Mire: bmire@renmarkfinancial.com
Welsh: lwelsh@renmarkfinancial.com
416-644-2020 or 514-939-3989